Mifepristone versus other interventions for the prevention of pregnancy in reproductive-age women using emergency contraception.
Shaalini Ramanadhan, Alison Edelman, Yan Che et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness, safety, and acceptability of mifepristone compared to other emergency contraception methods in reproductive-age women. The analysis included 87 studies with approximately 36,000 participants. Mid-dose mifepristone (25-50 mg) was associated with fewer pregnancies (risk ratio 0.67) and reduced side effects compared to levonorgestrel, both with moderate-certainty evidence.
Key findings
- Mid-dose mifepristone likely results in fewer pregnancies compared to levonorgestrel (RR 0.67).
- Low-dose mifepristone reduces pregnancy risk compared to levonorgestrel (RR 0.73).
- Low-dose mifepristone likely results in a large reduction in side effects (RR 0.26).
- Low-dose mifepristone probably leads to slightly higher treatment satisfaction (RR 1.03).
Why it matters
Understanding the comparative effectiveness and safety of emergency contraception options is crucial for reproductive healthcare providers. This evidence can guide clinicians in recommending the most effective and acceptable methods for preventing unintended pregnancies.